Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexeo Therapeutics, Inc. (LXEO) on April 28, 2026. The filing discloses the appointment of a new director to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Dr. Laura Sepp-Lorenzino to the Board of Directors effective April 28, 2026. She was also appointed as a member of the Science and Technology Committee. Her term expires at the 2028 Annual Meeting of Stockholders.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. The document details the compensatory arrangements for the new director:
- Cash Compensation: $40,000 annual cash compensation for Board service, plus additional cash for committee service.
- Equity Compensation: An initial stock option award for 50,000 shares granted on the appointment date.
- Future Grants: Eligible for an annual option to purchase 25,000 shares starting with the 2027 annual meeting. She is not eligible for an annual grant at the 2026 meeting due to the timing of her appointment.
Dr. Sepp-Lorenzino brings significant industry experience, having previously served as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc., and held leadership roles at Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck & Co.
Key Facts for Investor Verification
- Verify the impact of the new director's expertise in genomic medicine and nucleic acid therapies on the Company's strategic direction.
- Confirm the dilution impact of the 50,000 initial stock options and future annual grants on existing shareholders.
- Review the Company's Non-Employee Director Compensation Policy to understand the total potential cost of director compensation.
- Check for any subsequent filings regarding the 2026 Annual Meeting of Stockholders to confirm the timing of future equity grants.